Gonçalves Beatriz, Costeira Beatriz, Fonseca Filipa, Cabral Francisco, Caiado André, Cavadas Daniela, Maciel João, Limbert Manuel
Department of General Surgery, Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG), R. Prof. Lima Basto, 1099-023 Lisboa, Portugal.
J Clin Med. 2025 Jun 10;14(12):4097. doi: 10.3390/jcm14124097.
: Hand-assisted laparoscopic surgery (HALS) is a possible approach for rectal anterior resection (RAR). However, evidence supporting this technique remains limited. This study aims to evaluate the perioperative and oncological outcomes of HALS for RAR at a single tertiary oncology center. : A retrospective observational study was conducted using a prospectively maintained database. Patients with primary adenocarcinoma of the rectosigmoid junction and rectum who underwent HALS for RAR between 1 January 2013 and 31 December 2022 were included. All surgeries were performed by a dedicated colorectal team composed of three surgeons. : Among the 1911 surgeries for primary colorectal cancer performed, 469 met the inclusion criteria. The median age was 66 (57-74) years and 63% of the patients were male. Most tumors were cT3-4 (78.9%) and cN+ (71.2%), and neoadjuvant therapy was administered in 70.0% of cases. Low RAR was performed in 73.1% of cases, and an anastomosis was constructed in 95% of cases. The median operative time was 152 (135-180) min, and the conversion rate was 3.8%. Major morbidity occurred in 10.0% of cases, with 30-day and 90-day mortality rates of 0.9% and 1.3%, respectively. The overall anastomotic leak rate was 12.1%, with 9.0% early leaks and 3.1% late leaks. A complete/near-complete mesorectal excision was achieved in 89.6% of cases and an R0 resection in 96.2% of cases. With a median follow-up of 87 months, the locoregional recurrence rate was 2.5%, whereas the distant recurrence rate was 5.9%. The 5-year overall survival was 82.6%. : When performed by experienced teams, HALS for RAR is safe and feasible and is associated with a short operative time, low conversion rate, minimal morbidity, and optimal oncologic performance.
手辅助腹腔镜手术(HALS)是直肠前切除术(RAR)的一种可行方法。然而,支持该技术的证据仍然有限。本研究旨在评估在单一三级肿瘤中心行HALS治疗RAR的围手术期和肿瘤学结局。
采用前瞻性维护的数据库进行回顾性观察研究。纳入2013年1月1日至2022年12月31日期间因RAR接受HALS治疗的直肠乙状结肠交界处和直肠原发性腺癌患者。所有手术均由由三名外科医生组成的专业结直肠团队进行。
在1911例原发性结直肠癌手术中,469例符合纳入标准。中位年龄为66(57 - 74)岁,63%的患者为男性。大多数肿瘤为cT3 - 4(78.9%)和cN +(71.2%),70.0%的病例接受了新辅助治疗。73.1%的病例进行了低位RAR,95%的病例进行了吻合。中位手术时间为152(135 - 180)分钟,中转率为3.8%。10.0%的病例发生了严重并发症,30天和90天死亡率分别为0.9%和1.3%。总体吻合口漏率为12.1%,早期漏率为9.0%,晚期漏率为3.1%。89.6%的病例实现了完整/近完整直肠系膜切除,96.2%的病例实现了R0切除。中位随访87个月,局部复发率为2.5%,远处复发率为5.9%。5年总生存率为82.6%。
由经验丰富的团队进行时,HALS治疗RAR是安全可行的,且手术时间短、中转率低、并发症少、肿瘤学表现良好。